Active substance
Circadin is indicated as monotherapy for the short-term treatment of primary insomnia characterised by poor quality of sleep in patients who are aged 55 or over.
Slenyto is indicated for: treatment of insomnia in children and adolescents aged 2-18 years with Autism Spectrum Disorder (ASD), and / or neurogenetic disorders with aberrant diurnal melatonin secretion and /or nocturnal awakenings, where sleep hygiene measures have been insufficient. treatment of insomnia in children and adolescents aged 6-17 years with attention-deficit hyperactivity disorder (ADHD) where sleep hygiene measures have been insufficient.
Melatonin Neurim is indicated as monotherapy for the short-term treatment of primary insomnia characterised by poor quality of sleep in patients who are aged 55 or over.
| Source | Product as listed | Price | Unit / pack | Date |
|---|---|---|---|---|
| NHS Drug Tariff | Melatonin 1mg modified-release tablets | £32.96 | 60 tablet | 1 Oct 2026 |
| NHS Drug Tariff | Melatonin 1mg tablets | £10.89 | 30 tablet | 1 Oct 2026 |
| NHS Drug Tariff | Melatonin 1mg/ml oral solution sugar free | £9.81 | 150 ml | 1 Oct 2026 |
| NHS Drug Tariff | Melatonin 2mg capsules | £57.50 | 30 capsule | 1 Oct 2026 |
| NHS Drug Tariff | Melatonin 2mg modified-release tablets | £2.55 | 30 tablet | 1 Oct 2026 |
| NHS Drug Tariff | Melatonin 2mg tablets | £10.89 | 30 tablet | 1 Oct 2026 |
| NHS Drug Tariff | Melatonin 2mg/ml oral solution sugar free | £55.00 | 25 ml | 1 Oct 2026 |
| NHS Drug Tariff | Melatonin 3mg capsules | £62.50 | 30 capsule | 1 Oct 2026 |
| NHS Drug Tariff | Melatonin 3mg tablets | £7.38 | 30 tablet | 1 Oct 2026 |
| NHS Drug Tariff | Melatonin 4mg tablets | £10.89 | 30 tablet | 1 Oct 2026 |
| NHS Drug Tariff | Melatonin 5mg capsules | £105.00 | 30 capsule | 1 Oct 2026 |
| NHS Drug Tariff | Melatonin 5mg modified-release tablets | £82.40 | 30 tablet | 1 Oct 2026 |
NADAC: average price US retail pharmacies pay to buy the medicine. NHS Drug Tariff Part VIIIA: basic price reimbursed to pharmacies in England and Wales.
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.